How many doses are in a Mounjaro pen?

So there are exactly four doses, but does that change with the strength?

No. Whether you're looking at a 2.5 mg pen or a 15 mg pen, the dose count is identical: four injections, one per week, delivered on the same day each week. Eli Lilly designed the KwikPen this way across the entire range, so every pen in the Mounjaro treatment range covers precisely four weeks. The difference between a 5 mg pen and a 10 mg pen isn't the number of doses, it's the concentration of tirzepatide in each one.

That consistency is actually useful. When your prescriber moves you to a higher strength, you order one new pen and the four-week rhythm continues without interruption. If you're curious about how many doses sit inside a Mounjaro pen, the answer is the same regardless of which strength you're holding. The pen runs out the same week you'd be due a new prescription anyway.

If you want to read about how this plays out specifically at the 7.5 mg strength (which sits in the middle of the titration ladder) the dose count at 7.5 mg follows the same rule. Four doses. Same pen format.

Does using fewer injections make a pen last longer?

This is a question our prescribers hear fairly regularly, and the honest answer is: the pen isn't designed that way. The KwikPen delivers a fixed, pre-measured dose each time you press the button. You can't dial down the amount delivered per injection or skip one to stretch the pen across five weeks. Each click is one dose.

If doses are missed (for any reason, whether illness, travel, or simply forgetting) the right course of action is to follow the NHS patient guidance on tirzepatide and your Patient Information Leaflet, not to try to redistribute the remaining injections. Prescribers are best placed to advise on what to do after a missed dose; it's genuinely worth a quick message to your clinical team rather than guessing.

The pen locks automatically after the fourth dose, so there's a built-in safeguard. Once it's used, it's finished, it can't be primed again. Dispose of used pens safely in a sharps container; household bins aren't appropriate for used injection devices.

Which strength pen is right for a given point in treatment?

The prescriber decides, not the patient, and that's a meaningful distinction. The licensed schedule starts at 2.5 mg for the first four weeks, with the purpose of settling your system before any dose increase. It's a tolerability step. The treatment works by gradually titrating through the available strengths, typically in four-week steps, until you reach the highest strength that suits you clinically.

If you want to understand the 5 mg step in detail, the 5 mg Mounjaro page covers what that phase looks like. For a broader picture of how doses fit into the overall programme, the full dose guide walks through the titration schedule from start to finish.

One practical point worth flagging: what a specific strength costs, and how that fits into the wider landscape of weight-loss treatment options, is a reasonable thing to look into before starting. Treatment is a monthly commitment, and understanding the full picture matters.

How does knowing the dose count help when ordering a repeat?

Straightforwardly: four doses per pen means one pen equals one month of treatment, and if you want a detailed breakdown of how many doses are in one Mounjaro pen, that figure holds firm across every strength in the range. There's no mental arithmetic about whether you have doses left over from last time.

At a regulated UK pharmacy like ours, every repeat order goes through a fresh clinical review before dispatch. That matters because your prescriber isn't simply rubber-stamping a continuation; they're checking that the current strength is still appropriate, that you're not experiencing anything that warrants a pause, and that you're progressing as expected. More on how that process works is on the about us page.

The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% weight loss has occurred after six months at the highest tolerated dose, continuing the medicine should be reviewed. That's a clinical decision, exactly the kind of thing a prescriber weighs at each repeat, rather than something a patient has to self-monitor against. It reinforces why the repeat review exists, and why it's more than a formality.

If you're ready to start treatment or want to discuss which strength might suit your situation, speak to our prescribers through a free consultation.